Strides Pharma Science Ltd

Strides Pharma Science Ltd has successfully completed the transaction for its partnership with Ascent Capital concerning Pivot Path. The deal involved selling a majority stake in Pivot Path to a consortium led by Ascent Capital and co-investor Vintage Classic for approximately ₹1,000 million. Strides has received ₹750 million upfront, with the remaining ₹250 million due on the first anniversary of the closing date. Following this transaction, Pivot Path is no longer a wholly-owned subsidiary and will be classified as an associate company from July 1, 2026.

Strides Pharma Science Ltd. has announced a strategic investment by Ascent Capital and Vintage Classic in its subsidiary, Pivot Path Private Limited. The transaction values Pivot Path at approximately ₹2,300 million post-money, allowing Strides to realize around ₹1,000 million while retaining a 20% stake. Additionally, Pivot Path will receive ₹500 million in primary capital to fuel its growth and technology investments. This move aligns with Strides' strategy to unlock value from high-potential businesses. Pivot Path, which originated from Strides' Global Capability Centre, offers services in life sciences consulting, digital transformation, and technology. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million. Following the transaction, Pivot Path will be reclassified as an Associate of Strides Pharma Science Ltd.

Strides Pharma Science Limited's Board of Directors has approved a strategic investment by a consortium led by Ascent Capital and co-investor Vintage Classic in its subsidiary, Pivot Path Private Limited. The deal involves the sale of a majority stake in Pivot Path by Strides for an aggregate consideration of approximately ₹1,000 million, with an additional primary infusion of ₹500 million into Pivot Path by Ascent Capital to fund its growth. Following the transaction, Pivot Path will be reclassified as an Associate Company. The sale consideration will be paid in two tranches: ₹750 million at initial closing and ₹250 million on the first anniversary. The transaction is expected to be completed by June 30, 2026, for the share sale and by July 31, 2026, for the primary infusion.

Strides Pharma Science Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 1, 2026, and will reopen 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Strides Pharma Science Ltd announced that the scheme of demerger involving Arco Lab Private Limited and Pivot Path Private Limited has become effective from June 1, 2026. This follows the NCLT approval granted on May 20, 2026, and the receipt of the certified copy of the NCLT Order on May 25, 2026. The scheme became effective after filing the certified true copy of the order with the Registrar of Companies by Arco Lab and Pivot Path.

The USFDA conducted a routine cGMP inspection at Strides Pharma Science Ltd's Bangalore facility from May 12, 2026, to May 20, 2026. At the conclusion of the inspection, the U.S. FDA issued a Form 483 with five observations. The company will respond to the FDA within the stipulated time.

Strides Pharma Science Ltd. announced changes to its Board of Directors, KMP, and SMP, effective June 1, 2026. Venkata Seetharama Raju Pakalapati is elevated to Executive Director and KMP. Aditya Arun Kumar is redesignated as Non-Executive Director. Nandini Matiyani and Ariff Khan are nominated as SMPs. These changes reflect the company's succession planning and executive management strengthening.

The National Company Law Tribunal (NCLT) Bengaluru Bench has approved the Scheme of Arrangement for the demerger of the Demerged Undertaking of Arco Lab Private Limited, a wholly-owned subsidiary of Strides Pharma Science Limited, into Pivot Path Private Limited. The final order was made available on the NCLT portal on May 20, 2026. Upon receipt of the certified order and filing with the Registrar of Companies, the Scheme will become effective. Pivot Path will become a wholly-owned subsidiary of Strides, and its shares will be allotted to Strides as per the Scheme. The Demerged Undertaking from Arco Lab will vest with Pivot Path effective April 10, 2025.

Strides Pharma Science Ltd. announced changes to its Board of Directors, Key Managerial Personnel (KMP), and Senior Management Personnel (SMP) effective June 1, 2026. Venkata Seetharama Raju Pakalapati is elevated to Executive Director and KMP, while Aditya Arun Kumar is redesignated as a Non-Executive Director. Nandini Matiyani and Ariff Khan are nominated as SMP. These changes reflect the company's succession planning and executive management strengthening.

Strides Pharma Science Ltd's board approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹5 per equity share (50%) for FY26. The record date for dividend eligibility will be fixed and announced later. The dividend payment is subject to shareholder approval and tax deduction, payable within 30 days of AGM approval.